SARS-CoV-2 Vaccines and Multiple Sclerosis: An Update.
Open Access CRIS of the University of Bern · 2025-05-01
DOI: 10.48620/88175 ↗At a glance
Journal article in Open Access CRIS of the University of Bern, published on 2025-05-01. Written by Tobias Monschein and 9 co-authors.
Abstract (original language)
The highly contagious zoonosis coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was declared a pandemic by the World Health Organization on March 11, 2020, and has led to a global health crisis with nearly 777 million confirmed infections and over 7 million deaths worldwide by November 10, 2024.1-3 Over time, various variants emerged, with Omicron and its sublines dominating the world over the past 3 years.4 In addition, there is increasing evidence regarding the immune response of SARS-CoV-2 vaccines, especially for people with multiple sclerosis (MS) receiving disease-modifying therapies. Hence, with this review, we aim to provide an updated overview and recommendations for clinical practice regarding MS and SARS-CoV-2 vaccines, including efficacy and safety, SARS-CoV-2 variants, vaccine hesitancy, and the immune response under treatment with respective disease-modifying therapies.
Subjects
Cite
APA
Monschein, T., Zrzavy, T., Rommer, P. S., Meuth, G, S., Chan, A., Berger, Thomas, Hartung, & Hans-Peter (2025). SARS-CoV-2 Vaccines and Multiple Sclerosis: An Update. Open Access CRIS of the University of Bern. https://doi.org/10.48620/88175
Vancouver
Monschein T, Zrzavy T, Rommer PS, Meuth, G S, Chan A, et al. SARS-CoV-2 Vaccines and Multiple Sclerosis: An Update. Open Access CRIS of the University of Bern. 2025. doi:10.48620/88175
BibTeX
@article{Monschein2025,
author = {Monschein, Tobias and Zrzavy, Tobias and Rommer, Paulus Stefan and Meuth and G, Sven and Chan, Andrew and Berger and Thomas and Hartung and Hans-Peter},
title = {SARS-CoV-2 Vaccines and Multiple Sclerosis: An Update},
journal = {Open Access CRIS of the University of Bern},
year = {2025},
doi = {10.48620/88175}
}
EUVIMED